Comparison of outcomes after switching treatment from intravitreal bevacizumab to ranibizumab in neovascular age-related macular degeneration.

Objective: To compare visual acuity and central retinal thickness in patients initially treated with bevacizumab (Avastin) and switched to ranibizumab (Lucentis) for neovascular age-related macular degeneration (AMD).

Design: A retrospective chart review.

Participants: This study included 87 eyes from 80 patients over the age of 65 with neovascular AMD.